Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company dedicated to improving the lives of individuals with serious medical conditions. Its mission is to develop and commercialize innovative medicines that address unmet needs while responsibly managing the risks associated with opioid therapies. The company's global headquarters are located in Stoughton, Massachusetts.

Initially recognized for its leadership in responsible pain management through abuse-deterrent formulations, Collegium Pharmaceutical has significantly expanded its focus into neuropsychiatry, particularly in the Attention Deficit Hyperactivity Disorder (ADHD) market. Key products in its portfolio include Xtampza ER, Belbuca, Nucynta ER, Nucynta IR, and Symproic for pain management. The company's neuropsychiatry offerings feature Jornay PM and, following a recent acquisition, AZSTARYS®.

In a notable development, Collegium Pharmaceutical acquired AZSTARYS® from Corium Therapeutics on March 19, 2026, further solidifying its presence and growth trajectory in the ADHD therapeutic area. This follows the 2024 acquisition of Ironshore Therapeutics, which brought Jornay PM into its portfolio, and the 2022 acquisition of BioDelivery Sciences International (BDSI). The company is led by President and CEO Vikram Karnani, who joined in November 2024, and is positioned as a leader in both responsible pain management and a rapidly expanding neuropsychiatry business.